The Claim
RBSP3 down-regulation in non-small cell lung cancer is associated with both genetic deletions and epigenetic promoter methylation, with promoter methylation detected in 80% of squamous cell carcinomas and 38% of adenocarcinomas exhibiting reduced RBSP3 expression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In non-small cell lung cancer, reduced RBSP3 gene activity is linked to the loss of gene segments and chemical modifications on the gene's regulatory region; these modifications occur in 80% of squamous cell carcinomas and 38% of adenocarcinomas with low RBSP3 levels.
See the scientific wording
RBSP3 down-regulation in non-small cell lung cancer is associated with both genetic deletions and epigenetic promoter methylation, with methylation detected in 80% of squamous cell carcinomas and 38% of adenocarcinomas with reduced expression.
In some lung tumors, a piece of DNA containing the RBSP3 gene is missing, and the remaining copy is chemically marked so it cannot be read. This double hit stops the cell from making the RBSP3 protein, which normally holds cell growth in check. Without it, cells divide uncontrollably and form cancer.
What the research says
1 studyStudy: Solubilization and characterization of the κ-opioid receptor type from guinea-pig cerebellum
The study found that in lung cancers where the RBSP3 gene is turned off, it’s often because the gene is either deleted or chemically silenced by methylation — and this silencing happens much more often in squamous cell lung cancer than in adenocarcinoma, exactly as the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.